Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NASDAQ:CTSO NASDAQ:STIM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$2.16-5.3%$1.74$0.76▼$2.73$86.17M1.3184,361 shs234,696 shsCTSOCytosorbents$1.14+2.7%$1.01$0.71▼$1.61$69.50M1.19146,575 shs110,452 shsSTIMNeuronetics$3.54+1.1%$3.85$0.52▼$5.92$231.40M1.85826,272 shs651,936 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical-5.26%-5.84%+18.68%+123.83%+62.41%CTSOCytosorbents+2.70%+9.62%+7.55%+17.28%+15.16%STIMNeuronetics+1.14%+3.96%-6.60%-6.60%+91.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical1.7576 of 5 stars0.05.00.04.20.01.70.6CTSOCytosorbents2.0111 of 5 stars3.52.00.00.02.30.00.6STIMNeuronetics1.6907 of 5 stars3.32.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/ACTSOCytosorbents 3.00Buy$5.50382.46% UpsideSTIMNeuronetics 2.67Moderate Buy$5.5055.37% UpsideCurrent Analyst Ratings BreakdownLatest STIM, CTSO, and APYX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/15/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/15/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.005/2/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$48.10M1.70N/AN/A$0.38 per share5.68CTSOCytosorbents$35.60M2.00N/AN/A$0.20 per share5.70STIMNeuronetics$74.89M3.12N/AN/A$0.57 per share6.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.55N/AN/AN/A-42.37%-156.85%-31.92%8/6/2025 (Estimated)CTSOCytosorbents-$20.72M-$0.28N/AN/AN/A-41.77%-105.04%-29.18%8/12/2025 (Estimated)STIMNeuronetics-$43.71M-$1.31N/AN/AN/A-53.67%-174.15%-38.41%8/11/2025 (Estimated)Latest STIM, CTSO, and APYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CTSOCytosorbents-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million5/8/2025Q1 2025APYXApyx Medical-$0.13-$0.10+$0.03-$0.10$9.39 million$9.43 million5/6/2025Q1 2025STIMNeuronetics-$0.13-$0.21-$0.08-$0.21$29.07 million$31.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ACTSOCytosorbentsN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical3.215.454.64CTSOCytosorbents0.982.612.30STIMNeuronetics1.402.442.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%CTSOCytosorbents32.87%STIMNeuronetics53.59%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%CTSOCytosorbents7.30%STIMNeuronetics8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.79 million32.05 millionOptionableCTSOCytosorbents22062.61 million58.04 millionOptionableSTIMNeuronetics18066.11 million60.36 millionOptionableSTIM, CTSO, and APYX HeadlinesRecent News About These CompaniesNeuronetics Showcases NeuroStar TMS Data at Clinical TMS MeetingJuly 10 at 3:45 AM | msn.comAssenagon Asset Management S.A. Acquires Shares of 97,656 Neuronetics, Inc. (NASDAQ:STIM)June 20, 2025 | marketbeat.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 19, 2025 | globenewswire.comNeuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial ProgramJune 10, 2025 | globenewswire.comNeuronetics, Inc. to Join Russell 3000® and Russell 2000® Indexes Effective June 30, 2025June 3, 2025 | nasdaq.comNeuronetics to join Russell 3000 and Russell 2000 indexesJune 2, 2025 | msn.comNeuronetics Set to Join Russell 2000® and Russell 3000® IndexesJune 2, 2025 | globenewswire.comNeuronetics, Inc. (NASDAQ:STIM) EVP Sells $826,074.20 in StockMay 15, 2025 | insidertrades.comNeuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness MonthMay 14, 2025 | tmcnet.comNeuronetics Announces Inducement Awards for New Team MembersMay 10, 2025 | msn.comNeuronetics, Inc. (NASDAQ:STIM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$6.83May 9, 2025 | finance.yahoo.comEarnings call transcript: Neuronetics Q1 2025 misses EPS, stock drops 22%May 7, 2025 | investing.comNeuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook AcquisitionMay 7, 2025 | nasdaq.comNeuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook AcquisitionMay 7, 2025 | nasdaq.comNeuronetics Inc (STIM) Q1 2025 Earnings Call Highlights: Revenue Surge Amidst Margin ChallengesMay 7, 2025 | finance.yahoo.comNeuronetics, Inc. (STIM) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comNeuronetics (STIM) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comNeuronetics Reports First Quarter 2025 Financial and Operating ResultsMay 6, 2025 | globenewswire.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 5, 2025 | globenewswire.comWhy Neuronetics, Inc. (STIM) is Surging in 2025April 30, 2025 | msn.comNeuronetics to Announce Q1 2025 Results and Host Live Conference Call on May 6April 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBy Leo Miller | June 12, 2025View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayGitLab: Buy It Low While You Still Can—Higher Prices Are ComingBy Thomas Hughes | June 11, 2025View GitLab: Buy It Low While You Still Can—Higher Prices Are ComingWhy Analysts Are Bullish on Celsius Stock After 30% DropBy Gabriel Osorio-Mazilli | June 16, 2025View Why Analysts Are Bullish on Celsius Stock After 30% DropLululemon Slips as Rivals Rally: 3 Stocks to WatchBy Dan Schmidt | June 30, 2025View Lululemon Slips as Rivals Rally: 3 Stocks to WatchSTIM, CTSO, and APYX Company DescriptionsApyx Medical NASDAQ:APYX$2.16 -0.12 (-5.26%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$2.07 -0.09 (-4.17%) As of 07/10/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Cytosorbents NASDAQ:CTSO$1.14 +0.03 (+2.70%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$1.11 -0.03 (-2.98%) As of 05:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Neuronetics NASDAQ:STIM$3.54 +0.04 (+1.14%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$3.52 -0.02 (-0.42%) As of 05:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
